Chemomab Therapeutics Ltd
CMMB1.890USD
-0.030-1.56%
收盤 12/19, 16:00（美東）報價延遲15分鐘
46.53M總市值
虧損本益比TTM
關於 Chemomab Therapeutics Ltd 公司
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd簡介
公司代碼CMMB
公司名稱Chemomab Therapeutics Ltd
上市日期Aug 14, 2012
CEOMor (Adi)
員工數量16
證券類型Depository Receipt
年結日Aug 14
公司地址Kiryat Atidim, Building 7
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編6158002
電話972773310156
網址https://www.chemomab.com/
公司代碼CMMB
上市日期Aug 14, 2012
CEOMor (Adi)
Chemomab Therapeutics Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月18日 週二
更新時間: 11月18日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
其他
79.66%
持股股東
持股股東
佔比
Otto (Erik)
6.86%
Apeiron Investment Group Ltd
4.60%
Rivendell Investments 2017-9 LLC
4.50%
Sphera Funds Management Ltd.
2.92%
Morgan Stanley & Co. LLC
1.46%
其他
79.66%
股東類型
持股股東
佔比
Individual Investor
9.55%
Family Office
4.60%
Corporation
4.50%
Hedge Fund
3.78%
Research Firm
1.91%
Investment Advisor/Hedge Fund
0.50%
Investment Advisor
0.16%
其他
75.00%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
30
390.31K
17.98%
--
2025Q3
30
390.31K
17.98%
-667.39K
2025Q2
30
1.06M
18.61%
+124.78K
2025Q1
31
932.92K
24.29%
-212.50K
2024Q4
32
1.04M
26.27%
-97.26K
2024Q3
29
1.14M
22.64%
+165.56K
2024Q2
28
668.24K
21.48%
+2.79K
2024Q1
32
666.14K
22.68%
-139.12K
2023Q4
33
705.36K
20.90%
+69.50K
2023Q3
33
635.85K
25.86%
-196.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Otto (Erik)
422.50K
8.17%
+133.75K
+46.32%
Aug 11, 2025
Apeiron Investment Group Ltd
283.00K
5.47%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
5.36%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
184.51K
3.57%
-40.59K
-18.03%
Jun 30, 2025
Morgan Stanley & Co. LLC
403.53K
7.8%
+374.24K
+1277.72%
Jun 30, 2025
Mor George (Adi)
79.27K
1.53%
--
--
Dec 31, 2024
Ikarian Capital LLC
53.26K
1.03%
--
--
Jun 30, 2025
George (Kobi)
50.06K
0.97%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.68%
-2.50K
-6.61%
Dec 31, 2024
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
公告日期
類型
比率
Aug 08, 2025
Merger
4→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
常見問題
Chemomab Therapeutics Ltd的前五大股東是誰？
Chemomab Therapeutics Ltd的前五大股東如下：
Otto (Erik)持有股份：422.50K佔總股份比例：8.17%。
Apeiron Investment Group Ltd持有股份：283.00K佔總股份比例：5.47%。
Rivendell Investments 2017-9 LLC持有股份：277.13K佔總股份比例：5.36%。
Sphera Funds Management Ltd.持有股份：184.51K佔總股份比例：3.57%。
Morgan Stanley & Co. LLC持有股份：403.53K佔總股份比例：7.80%。
Otto (Erik)持有股份：422.50K佔總股份比例：8.17%。
Apeiron Investment Group Ltd持有股份：283.00K佔總股份比例：5.47%。
Rivendell Investments 2017-9 LLC持有股份：277.13K佔總股份比例：5.36%。
Sphera Funds Management Ltd.持有股份：184.51K佔總股份比例：3.57%。
Morgan Stanley & Co. LLC持有股份：403.53K佔總股份比例：7.80%。
Chemomab Therapeutics Ltd的前三大股東類型是什麼？
Chemomab Therapeutics Ltd 的前三大股東類型分別是：
Otto (Erik)
Apeiron Investment Group Ltd
Rivendell Investments 2017-9 LLC
Otto (Erik)
Apeiron Investment Group Ltd
Rivendell Investments 2017-9 LLC
有多少機構持有Chemomab Therapeutics Ltd(CMMB)的股份？
截至2025Q4，共有30家機構持有Chemomab Therapeutics Ltd的股份，合計持有的股份價值約為390.31K，占公司總股份的17.98% 。與2025Q3相比，機構持股有所增加，增幅為--。
哪個業務部門對Chemomab Therapeutics Ltd的收入貢獻最大？
在--，--業務部門對Chemomab Therapeutics Ltd的收入貢獻最大，創收--，占總收入的--% 。
